Causal association between serum 25-Hydroxyvitamin D levels and cutaneous melanoma: a two-sample Mendelian randomization study.
Mendelian randomization
causal inference
cutaneous melanoma
genetic variants
serum 25-hydroxyvitamin D
sun exposure
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
01
2023
accepted:
03
08
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Despite numerous observational studies on the association between serum 25-Hydroxyvitamin D levels and cutaneous melanoma, causal inferences remain ambiguous due to confounding and reverse causality. This study aimed to elucidate the causal relationship between serum 25-Hydroxyvitamin D levels and melanoma incidence using Mendelian randomization (MR). A two-sample MR was conducted using genetic variants associated with serum 25-Hydroxyvitamin D levels as instrumental variables. Summary statistics for these variants were derived from genome-wide association studies, and those for melanoma risk were obtained from a comprehensive melanoma case-control study. Robustness of the results was assessed through sensitivity analyses, including the "leave-one-out" approach and tests for potential pleiotropy. The MR analysis provided substantial evidence of a positive causal relationship between serum 25-Hydroxyvitamin D levels and the incidence of cutaneous melanoma, suggesting that each unit increase in serum 25-Hydroxyvitamin D levels corresponds with an increased risk of melanoma. Tests for pleiotropy showed minimal effects, and the sensitivity analysis confirmed no disproportionate influence by any individual single nucleotide polymorphism (SNP). The findings indicated a potentially causal positive association between serum 25-Hydroxyvitamin D levels and melanoma risk, challenging traditional beliefs about vitamin D's role in melanoma. This emphasizes the need for a balanced and personalized approach to vitamin D supplementation and sun exposure, particularly in high-risk populations. These results should be interpreted with caution due to potential unrecognized pleiotropy and confounding factors. Future research should focus on validating these findings in diverse populations and exploring underlying biological mechanisms.
Sections du résumé
Background
UNASSIGNED
Despite numerous observational studies on the association between serum 25-Hydroxyvitamin D levels and cutaneous melanoma, causal inferences remain ambiguous due to confounding and reverse causality. This study aimed to elucidate the causal relationship between serum 25-Hydroxyvitamin D levels and melanoma incidence using Mendelian randomization (MR).
Methods
UNASSIGNED
A two-sample MR was conducted using genetic variants associated with serum 25-Hydroxyvitamin D levels as instrumental variables. Summary statistics for these variants were derived from genome-wide association studies, and those for melanoma risk were obtained from a comprehensive melanoma case-control study. Robustness of the results was assessed through sensitivity analyses, including the "leave-one-out" approach and tests for potential pleiotropy.
Results
UNASSIGNED
The MR analysis provided substantial evidence of a positive causal relationship between serum 25-Hydroxyvitamin D levels and the incidence of cutaneous melanoma, suggesting that each unit increase in serum 25-Hydroxyvitamin D levels corresponds with an increased risk of melanoma. Tests for pleiotropy showed minimal effects, and the sensitivity analysis confirmed no disproportionate influence by any individual single nucleotide polymorphism (SNP).
Conclusion
UNASSIGNED
The findings indicated a potentially causal positive association between serum 25-Hydroxyvitamin D levels and melanoma risk, challenging traditional beliefs about vitamin D's role in melanoma. This emphasizes the need for a balanced and personalized approach to vitamin D supplementation and sun exposure, particularly in high-risk populations. These results should be interpreted with caution due to potential unrecognized pleiotropy and confounding factors. Future research should focus on validating these findings in diverse populations and exploring underlying biological mechanisms.
Identifiants
pubmed: 37664026
doi: 10.3389/fonc.2023.1154107
pmc: PMC10470627
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1154107Informations de copyright
Copyright © 2023 Cai, Lin, Ke, Shan, Yu, Ni, Lin and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Melanoma Res. 2023 Aug 1;33(4):265-274
pubmed: 37199748
J Steroid Biochem Mol Biol. 2019 Feb;186:4-21
pubmed: 30205156
PLoS Genet. 2017 Nov 17;13(11):e1007081
pubmed: 29149188
Nucleic Acids Res. 2023 Jan 6;51(D1):D1160-D1167
pubmed: 35947748
J Surg Res. 1996 Feb 15;61(1):127-33
pubmed: 8769954
Stat Med. 2017 May 20;36(11):1783-1802
pubmed: 28114746
Anticancer Res. 2020 Jan;40(1):473-489
pubmed: 31892603
Genet Epidemiol. 2013 Nov;37(7):658-65
pubmed: 24114802
Nutrients. 2020 Mar 18;12(3):
pubmed: 32197412
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Eur J Cancer. 2005 Jan;41(1):45-60
pubmed: 15617990
J Steroid Biochem Mol Biol. 2018 Mar;177:159-170
pubmed: 28676457
J Clin Oncol. 2011 Aug 1;29(22):3078-84
pubmed: 21709199
Nutrients. 2021 Nov 11;13(11):
pubmed: 34836273
Gene. 2004 Sep 1;338(2):143-56
pubmed: 15315818
J Natl Cancer Inst. 2005 Feb 2;97(3):195-9
pubmed: 15687362
BMJ. 2018 Jul 12;362:k601
pubmed: 30002074
Am J Epidemiol. 2013 Oct 1;178(7):1177-84
pubmed: 23863760
FASEB J. 2012 Sep;26(9):3901-15
pubmed: 22683847
Eur J Epidemiol. 2017 May;32(5):377-389
pubmed: 28527048
Nat Genet. 2009 Oct;41(10):1088-93
pubmed: 19734902
Cancers (Basel). 2021 Jun 22;13(13):
pubmed: 34206371
J Anim Sci Biotechnol. 2017 May 2;8:38
pubmed: 28469846
Arch Biochem Biophys. 2012 Jul 1;523(1):9-18
pubmed: 22100522
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:207-14
pubmed: 24128439
Am J Clin Dermatol. 2022 May;23(3):331-338
pubmed: 35359259
Elife. 2018 May 30;7:
pubmed: 29846171
Nat Genet. 2018 Jul;50(7):906-908
pubmed: 29892013
Epidemiology. 2017 Jan;28(1):30-42
pubmed: 27749700
Lancet Diabetes Endocrinol. 2023 May;11(5):362-374
pubmed: 37004709
Int J Epidemiol. 2019 Jun 1;48(3):713-727
pubmed: 30535378
Pigment Cell Melanoma Res. 2018 Mar;31(2):287-296
pubmed: 28990310
Eur J Epidemiol. 2015 Jul;30(7):543-52
pubmed: 25773750
Front Oncol. 2021 Oct 06;11:743667
pubmed: 34692525
Int J Epidemiol. 2013 Oct;42(5):1497-501
pubmed: 24159078
N Engl J Med. 2021 Jun 10;384(23):2229-2240
pubmed: 34107182
Int J Epidemiol. 2020 Aug 1;49(4):1236-1245
pubmed: 32068838
Br J Dermatol. 2002 Aug;147(2):197-213
pubmed: 12174089
Stat Methods Med Res. 2017 Oct;26(5):2333-2355
pubmed: 26282889
Acta Biochim Pol. 2016;63(1):17-29
pubmed: 26824295
Bioinformatics. 2019 Nov 1;35(22):4851-4853
pubmed: 31233103
Lab Invest. 2017 Jun;97(6):706-724
pubmed: 28218743
J Invest Dermatol. 2009 Jul;129(7):1675-80
pubmed: 19194478
Signal Transduct Target Ther. 2021 Dec 20;6(1):424
pubmed: 34924562
Br J Dermatol. 2020 Jan;182(1):97-103
pubmed: 31218665
Int J Epidemiol. 2011 Jun;40(3):755-64
pubmed: 21414999
Adv Exp Med Biol. 2020;1268:143-154
pubmed: 32918217
Nat Rev Cancer. 2007 Sep;7(9):684-700
pubmed: 17721433
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Stat Med. 2011 May 20;30(11):1312-23
pubmed: 21432888
G Ital Dermatol Venereol. 2018 Oct;153(5):732-733
pubmed: 30246955
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
Nat Genet. 2018 Aug;50(8):1196
pubmed: 29967445
G Ital Dermatol Venereol. 2019 Feb;154(1):64-71
pubmed: 29249122
Hum Mol Genet. 2014 Sep 15;23(R1):R89-98
pubmed: 25064373
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Am J Public Health. 2006 Feb;96(2):252-61
pubmed: 16380576
Int J Epidemiol. 2017 Dec 1;46(6):1734-1739
pubmed: 28398548
Drugs. 2023 Jun;83(8):665-685
pubmed: 37148471
J Photochem Photobiol B. 2001 Oct;63(1-3):8-18
pubmed: 11684447
Int J Epidemiol. 2011 Jun;40(3):740-52
pubmed: 20813862
Bioinformatics. 2016 Oct 15;32(20):3207-3209
pubmed: 27318201
Dermatol Pract Concept. 2019 Dec 31;10(1):e2020010
pubmed: 31921497
Int J Epidemiol. 2018 Aug 1;47(4):1264-1278
pubmed: 29961852
Arch Biochem Biophys. 2023 Jul 1;742:109639
pubmed: 37196753
Nat Immunol. 2022 May;23(5):660-670
pubmed: 35241833
Sci Rep. 2020 Nov 18;10(1):20129
pubmed: 33208828
Wellcome Open Res. 2019 Nov 26;4:186
pubmed: 32760811
Sci Rep. 2020 Aug 4;10(1):13151
pubmed: 32753685
Eur J Cancer. 2014 Oct;50(15):2649-58
pubmed: 25087185
Nat Rev Cancer. 2023 Jun;23(6):372-390
pubmed: 37095242
PLoS Genet. 2018 May 21;14(5):e1007371
pubmed: 29782485
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1722-1729
pubmed: 31919907
Neoplasma. 2017;64(1):1-12
pubmed: 27880999
J Steroid Biochem Mol Biol. 2016 Nov;164:18-29
pubmed: 26686945
Pigment Cell Melanoma Res. 2022 Jul;35(4):408-424
pubmed: 35445563
JAMA Psychiatry. 2020 May 1;77(5):534-540
pubmed: 31774490
Int J Mol Sci. 2020 May 16;21(10):
pubmed: 32429485
J Clin Oncol. 2009 Nov 10;27(32):5439-44
pubmed: 19770375
Anticancer Res. 2020 Feb;40(2):583-595
pubmed: 32014899
Br J Dermatol. 2020 Jan;182(1):13-14
pubmed: 31782141
Hum Mol Genet. 2018 Aug 1;27(R2):R195-R208
pubmed: 29771313
Stat Med. 2015 Sep 20;34(21):2926-40
pubmed: 25950993
J Steroid Biochem Mol Biol. 2020 Feb;196:105500
pubmed: 31629064
Eur J Cancer. 2009 Dec;45(18):3271-81
pubmed: 19615888
Nutrients. 2021 Nov 28;13(12):
pubmed: 34959844
Eur J Cancer Prev. 2019 May;28(3):203-211
pubmed: 29438161